Ashish Aneja MD FACC FAHA FASE FSCMR

Associate Professor @CWRU, Director Noninvasive Cardio, Chair IRB, Director #CMR #HCM @MetroHealthCle #WhyCMR #echofirst #WhyCCT

[Ashish Aneja MD FACC FAHA FASE FSCMR @ash71us]

A poll for my noninvasive CMR peeps! What agent(s) do you use most frequently for CMR stress? @HeartDocSubha @DrRyanPDaly @AkhilNarangMD

[Collin Rugg @CollinRugg]

NEW: Students go nuts after donor announces during his commencement speech that he is paying off all of their senior year debts.

Anil Kochhar and his wife decided to give the gift to all ~200 graduates in N.C. State's family.

Kochhar is the son of Prakash Chand Kochhar, an immigrant from India who studied textile manufacturing in Raleigh.

"My father found not just an education, but an opportunity that allowed him to build a life, support his family, and begin a legacy that continues today. And it will never stop, never," Kochhar said.

[Dr. Purvi Parwani @purviparwani]

HI-PEITHO key takeaways #ACC26

🫀 Intermediate-risk PE = stable patients with RV strain + positive biomarkers
⚖️ ultrasound-facilitated catheter-directed thrombolysis + AC vs AC alone in this “gray-zone” group
📉 ↓ Early clinical deterioration: 4.0% vs 10.3%
🚑 Benefit driven by ↓ hemodynamic collapse—not mortality
🩸 No ↑ major bleeding or ICH → supports selective early intervention

[Dr. Purvi Parwani @purviparwani]

If you’re at #ACC26 and part of the #ACCimaging community, don’t miss our meet-up today at 2:30 PM (Meet-Up Zone 2).

Stop by, say hello, and catch up!

[Ashish Aneja MD FACC FAHA FASE FSCMR @ash71us]

@SaurabhSDani @SarjuGanatraMD Wonderful!

[Alka Kanaya @alka_kanaya]

Some new evidence comparing middle-aged US population groups with MASALA and MESA data…

[MASALA Study @masala_study]

At what age does CVD risk begin to diverge among South Asians compared to other groups? Understanding risk trajectories allows us to identify people who can benefit from prevention before CVD events.

[JAMA Neurology @JAMANeuro]

Among patients with #Stroke and #PatentForamenOvale, the PASCAL classification system identified those likely to benefit from closure and those at risk of increased atrial fibrillation. https://t.co/ydBeuC8MOe

[Roger Blumenthal @rblument1]

Great to celebrate our Preventive Cardiology Guideline release with my colleague & key writing group member ⁦@SethShayMartin⁩ - special thanks to the Prevention Dream Team Writing group & my co-chair, the Amazing Dr. Pam Morris

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Davide Capodanno @DFCapodanno]

Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs — something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests. This was driven by independent investigators. The results somewhat support the idea of apixaban being the “safer” DOAC. That said, the list of study limitations is long, and for me, labeling something as “safe” is not enough — after all, even placebo is “safe” when it comes to bleeding. https://t.co/eYehndGzvB

[Ahmed Bennis MD 🫀 @drbennisahmed]

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction
The APERITIF Randomized Clinical Trial

In this multicenter randomized clinical trial among patients with anterior STEMI, the addition of low-dose rivaroxaban to DAPT did not demonstrate a statistically significant reduction in LV thrombus formation at 1 month but did increase minor bleeding

#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@JAMA_current @CMichaelGibson @DrMarthaGulati @hvanspall @iamritu @AndrewJSauer @AnastasiaSMihai @biljana_parapid @Hragy
https://t.co/ACL0AQxZ5l

[EHJ Editor-in-Chief @ehj_ed]

Regular aspirin use and reduced risk of aortic valve calcium and severe aortic stenosis in individuals with elevated lipoprotein(a) levels!

https://t.co/3MbCxrlBUk

#EHJ #cardiotwitter #aspirin #aortic #stenosis #lipoprotein(a) @ESC_journals @escardio

[Roger Blumenthal @rblument1]

@AlexRazavi @seamuswhelton @MichaelJBlaha @WendyPost9 @CiccaroneCenter @hopkinsheart

[European Society of Cardiology Journals @ESC_Journals]

🆕 Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy 💡 see @ESCHeartFailure https://t.co/EcxOZsDOfj

@EJHFEiC @JanBiegus @Ppponikowski #HFA_ESC @hvanspall @ShelleyZieroth @FudimMarat @gcfmd @AlexMebazaa @MarcoMetra @GianluSava

[JACC Journals @JACCJournals]

🫀 In HCM, combining imaging biomarkers improves risk prediction! High LGE% + low LV-GLS ➡️ highest risk of CV events, including sudden cardiac death. Integrating structure & function aids precision stratification 🔬 https://t.co/3LgqnguarE

#JACCAsia #cvHCM #RiskStratification

[Annals of Int Med @AnnalsofIM]

NEW: A study of more than 46,000 patients with #AtrialFibrillation taking the blood thinners apixaban or rivaroxaban found that those who were also prescribed diltiazem had a higher risk of serious bleeding than those prescribed metoprolol. https://t.co/JYhGLUa4V5 @DawwasGhadeer @VUMCDiscoveries

[JACC Journals @JACCJournals]

Elevated Lp(a) increases the risk of abdominal aortic aneurysm (AAA), independent of #ApoB. Using UK Biobank & genetic analyses, Sharma et al. in #JACCBTS provide evidence that supports Lp(a) as a causal risk factor & potential therapeutic target for AAA. https://t.co/WyLb62fUzs

[European Society of Cardiology Journals @ESC_Journals]

Lipoprotein(a)-lowering therapies: a promising future. A state-of-the-Art review in #EHJ
👉 https://t.co/ae8NIerfro

@RoccoMontone @ehj_ed

[JAMA Cardiology @JAMACardio]

Very high lipoprotein(a) levels are associated with increased 30-year risk of major #cardiovascular events, coronary heart disease, ischemic #stroke, and cardiovascular death among healthy women.

https://t.co/nNDiLBKp3J

[Roger Blumenthal @rblument1]

Important paper led by Head Coach @MichaelJBlaha - the MJ23 of Prevention - & his all-star team on the globalCV impact of severe obesity on CVA, AF, & total CVD @ZeinaDardari @CiccaroneCenter @hopkinsheart